CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment

Data demonstrates the strength of Werewolf’s innovative therapeutic approach across multiple conditionally activated pipeline programs CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical

-Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program- -On Track to File Two INDs in First Half of 2022- CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced

Over 30 years of broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing, and externalization activities CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc.

Posters Detail Preclinical Data on the Company’s WTX-124 and WTX-330 Molecules for the Potential Treatment of Cancer CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally

CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced

Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, in combination with KEYTRUDA® (pembrolizumab) as a treatment for patients with solid tumors CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics,

CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment